Market Place
Sourcing Support
SK Bio Approved For Global Trials Of mRNA Encephalitis Vaccine
12 Dec 2024 //
PRESS RELEASE
SK Bio Receives Minister of Trade, Industry & Energy Award
29 Nov 2024 //
PRESS RELEASE
SK Bio applies for IND for domestic phase 3 clinical trial
29 Oct 2024 //
PRESS RELEASE
SK Bioscience Receives Approval For Quadrivalent Influenza Vaccine
23 Oct 2024 //
PRESS RELEASE
SK bioscience Acquires Stake in U.S. Biotech Fina Biosolutions
08 Oct 2024 //
PRESS RELEASE
SK bioscience Completes Acquisition of IDT Biologika
02 Oct 2024 //
PRESS RELEASE
Novavax COVID-19 Vaccine Expands Options, Approved For Use
30 Sep 2024 //
PRESS RELEASE
SK Bioscience And CEPI Deepen Partnership For Pandemic Preparedness
30 Aug 2024 //
PRESS RELEASE
SK Bioscience Signs SAFE With U.S. Biotech Sunflower
25 Jul 2024 //
PRESS RELEASE
SK bioscience Signs Power Purchase Agreement with SK E&S
16 Jul 2024 //
PRESS RELEASE
SK begins `globalization` push, paying $244M for majority stake in IDT Biologika
27 Jun 2024 //
FIERCE PHARMA
SK bioscience Exports Influenza Vaccine to Thailand, Southern Hemisphere
21 Mar 2024 //
PRESS RELEASE
SK bioscience exports influenza vaccine to Thailand, entering Southern market
21 Mar 2024 //
BIOSPECTRUM ASIA
SK bioscience Breaks Ground on Manufacturing Facility Expansion
07 Mar 2024 //
PR NEWSWIRE
SK bioscience Receives WHO Prequalification for Typhoid Conjugate Vaccine
23 Feb 2024 //
PR NEWSWIRE
PM of the Republic of Serbia Visits SK bioscience for Vaccine Localization
08 Sep 2023 //
PR NEWSWIRE
Australia-Korea joint devp agreement for needle-free of typhoid vaccine
29 Aug 2023 //
BIOSPECTRUM ASIA
SK bioscience Announces Equity Investment in Novavax to Strengthen Partnership
08 Aug 2023 //
PR NEWSWIRE
Novavax to sell 7% stake to South Korea`s SK Bioscience
08 Aug 2023 //
REUTERS
Korea`s SK inks deal to support vaccine production in Thailand
05 Jul 2023 //
FIERCE PHARMA
SK bioscience-Sanofi Announce Positive Results from Ph II Study of 21-Valent
29 Jun 2023 //
PR NEWSWIRE
SK bioscience, Peter Doherty Institute Partner on Influenza Research
26 Jun 2023 //
CONTRACT PHARMA
SK bioscience COVID-19 Vaccine Granted Emergency Use Listing by the WHO
19 Jun 2023 //
PR NEWSWIRE
SK bioscience COVID-19 Vaccine Granted Emergency Use by WHO
19 Jun 2023 //
CONTRACT PHARMA
SK bioscience Receives Marketing Authorization of COVID-19 Vaccine from UK MHRA
30 May 2023 //
PR NEWSWIRE
SK Bioscience gains UK authorisation for SKYCovion Covid-19 vaccine
30 May 2023 //
PHARMACEUTICAL TECHNOLOGY
SK bioscience Presents Solution for Equitable Access of Vaccine
23 May 2023 //
PR NEWSWIRE
SK bioscience Establishes Songdo Research & Process Development Center
09 Feb 2023 //
CONTRACT PHARMA
SK Bioscience plans $261M expansion in South Korea with new facility
09 Feb 2023 //
ENDPTS
SK bioscience to Establish a Vaccine-Biopharma Hub
09 Feb 2023 //
CONTRACT PHARMA
Readying for next pandemic, Korea`s SK pumps $261M into R&D site
08 Feb 2023 //
FIERCE BIOTECH
SK bioscience Introduces New Global Partnership Model for Vaccines
27 Jan 2023 //
CONTRACT PHARMA
SK bioscience`s Zoster Vaccine Receives BLA Approval in Malaysia
09 Jan 2023 //
PR NEWSWIRE
SK Bioscience suspends production of COVID-19 vaccine `Sky Covione`
24 Nov 2022 //
HEALTH ET
SK Bioscience`s Covid-19 vaccine losing against multinationals’ bivalent vaccine
10 Nov 2022 //
KOREABIOMED
SK bioscience unveils strategy aimed at global market expansion
03 Nov 2022 //
FIERCEPHARMA
SK bioscience and CEPI enter mRNA vaccine development deal
27 Oct 2022 //
PHARMACEUTICAL-TECHNOLOGY
CEPI and SK bioscience partner to advance mRNA vaccine technology
26 Oct 2022 //
INDIANPHARMAPOST
SK bioscience and CEPI Sign Agreement to Develop mRNA Vaccines
25 Oct 2022 //
PRNEWSWIRE
CEPI teams up with Korean vaccine maker in $140M pact
25 Oct 2022 //
ENDPTS
SK bioscience Appoints New Executives towards Global Business Growth
21 Oct 2022 //
PRNEWSWIRE
Novavax and SK bioscience File a Post Approval Change Application in South Korea
10 Oct 2022 //
PRESS RELEASE
Korea`s 1st homegrown COVID-19 vaccine maker underlines global partnership
03 Oct 2022 //
ASIANEWS
SK Bioscience applies for SKYCovione`s WHO emergency use listing
09 Sep 2022 //
KOREAHERALD
SK bioscience begins first shipment of Korean Covid-19 vaccine, SKYCovione
03 Sep 2022 //
PHARMABIZ
SK Bioscience`s SKYCovione proven effective against omicron virus subvariants
02 Sep 2022 //
INFORMA
World Health Organization Approves SK bioscience as a Supplier of Novavax Nuvaxovid™ COVID-19 Vaccine
02 Sep 2022 //
PRESS RELEASE
Novavax’s Covid-19 vaccine gets approval in South Korea for adolescents
15 Aug 2022 //
PHARMACEUTICAL-TECHNOLOGY
SK bioscience Covid-19 vaccine active against BA.1 variant in Phase I/II trial
14 Jul 2022 //
CLINICALTRIALSARENA
EMA Approves SK bioscience as a Supplier of Novavax Nuvaxovid
07 Jul 2022 //
PRESS RELEASE
S.Korea approves first domestically developed COVID vaccine
28 Jun 2022 //
REUTERS
GSK and SK bioscience`s COVID vaccine submitted for S.Korea approval
29 Apr 2022 //
REUTERS
SK advances Gates-backed COVID-19 antiviral spray toward clinic
19 Apr 2022 //
FIERCEPHARMA
South Korea Ministry of Food and Drug Safety approves Novavax COVID-19 vaccine
13 Jan 2022 //
PHARMAFILE
SK takes out stake in cell & gene therapy CDMO with plans for major hiring spree
11 Jan 2022 //
ENDPTS
S. Korean drug firms rush to develop vaccines effective against omicron
18 Dec 2021 //
KOREAHERALD
South Korean drugmaker SK looks to take over Philly CDMO`s operations
18 Nov 2021 //
ENDPTS
Novavax and SK bioscience submit BLA for Covid-19 vaccine in South Korea
15 Nov 2021 //
PHARMACEUTICAL-TECHNOLOGY
SK bioscience & CEPI Extend Agreement, COVID-19 Vaccine by the End of 2022
06 Oct 2021 //
YNA
SK Bioscience likely to secure vaccine supply deal from COVAX next year: report
15 Sep 2021 //
KOREAHERALD
